About Nav Businesses Nav Investor Relations Products media
Media Room
Home > Media Room > News Releases

News Releases

Archives: Search / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004 / 2003 / 2002

2008 Archives
Dec 30, 2008
Mylan's Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit® Capsules
Dec 12, 2008
Mylan Announces Move to NASDAQ Stock Market
- Mylan will maintain 'MYL' symbol -
Dec 2, 2008
Mylan Announces Settlement Agreement with Novartis Related to Femara® First- to-File Opportunity
Dec 1, 2008
Mylan Confirms First-to-File Patent Challenge Relating to AMRIX®
- Mylan believes it has 180 days of sole marketing exclusivity -
Nov 18, 2008
Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem® Pulvules® Capsules
Nov 17, 2008
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR®
Nov 6, 2008
Mylan's Dey L.P. Announces Establishment of 'J-Code' for Perforomist™ Inhalation Solution
Nov 4, 2008
Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra® and Launches Immediately
Oct 30, 2008
Mylan Declares Quarterly Preferred Stock Dividend
Oct 30, 2008
Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Increases 2008 Adjusted EPS Guidance to $0.64 - $0.67 from Prior Range of $0.47 - $0.53
Oct 29, 2008
Mylan's Matrix First-to-File on Generic Version of Vfend® Antifungal
- No lawsuit filed within statutory 45-day window -
Oct 22, 2008
Mylan Receives Tentative FDA Approval for First-to-File Generic Version of Blood Pressure Drug Benicar HCT®
- Mylan also announces tentative approval for generic version of Uroxatral® ER -
Oct 22, 2008
Mylan Confirms First-to-File Patent Challenge Relating to Lescol®
Oct 16, 2008
Mylan Schedules Third Quarter Financial Results Conference Call and Live Webcast
Oct 9, 2008
Mylan Announces $500 Million of Floating Rate Debt Swapped to Fixed Rates
Exposure to short-term LIBOR rate borrowings reduced to approximately $850 million
Sep 22, 2008
Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Parcopa® ODT
Represents Another Mylan First-to-Market Opportunity
Sep 16, 2008
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal®
Sep 15, 2008
Mylan Completes $575 Million Cash Convertible Note Offering, Including Exercise of Overallotment Option
Sep 10, 2008
Mylan Prices $500 Million Cash Convertible Notes due 2015
Sep 8, 2008
Mylan to Offer $400 Million in Cash Convertible Notes
Sep 8, 2008
Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
Mylan reaffirms adjusted diluted EPS guidance for '08, '09, '10
Aug 29, 2008
Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne® Tablets
Receives FDA Approval for Generic Version
Aug 11, 2008
Mylan Named Manufacturer of the Year by AmerisourceBergen Corporation
Aug 6, 2008
Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
- Mylan Increases Adjusted EPS Guidance for 2008 to $0.47 - $0.53
Aug 6, 2008
Mylan Creates New Women's Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
1-25      26-50      51-57
 

The news releases on this page are included for historical puposes only. The information contained in each press release speaks only as of the date thereof and assumes no duty to update such information beyond the dates thereof.


 Email Page    Print